Funding for this research was provided by:
National Institutes of Health (R35 CA197735)
Hale Center for Pancreatic Cancer Research (-)
National Cancer Institute (U01 CA210171, P50 CA127003)
U.S. Department of Defense (CA130288)
Lustgarten Foundation (-)
Pancreatic Cancer Action Network (-)
Stand Up To Cancer (-)
Noble Effort Fund (-)
Peter R. Leavitt Family Fund (-)
Wexler Family Fund (-)
Promises for Purple (-)
Article History
Received: 27 January 2020
Accepted: 29 January 2020
First Online: 14 February 2020
Compliance with ethical standards
:
: BMW declares research funding from Celgene Inc., and consulting for BioLineRx Ltd., G1 Therapeutics Inc., and GRAIL Inc.. This manuscript was not funded by any of those companies. No other conflicts of interest exist. The other authors declare that they have no conflicts of interest.